INSM vs. ROIV: Insmed vs. Roivant Sciences Stock Comparison
How do Insmed (INSM) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Insmed (INSM) and Roivant Sciences (ROIV) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Insmed (INSM) has more than two decades of public-market history since June 1, 2000, whereas Roivant Sciences (ROIV) listed on December 8, 2020 and has a much shorter record to draw on.
| Profile Item | INSM | ROIV |
|---|---|---|
| Name | Insmed Incorporated | Roivant Sciences Ltd. |
| Country/Region | United States | United Kingdom |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 25.10 billion USD | 28.08 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2000 | December 8, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | INSM | ROIV |
|---|---|---|
| Total Return (1Y) | -39.17% | 96.75% |
| Total Return (3Y, Annualized) | 70.17% | 68.04% |
| Total Return (5Y, Annualized) | 28.96% | 36.73% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | INSM | ROIV |
|---|---|---|
| Volatility (1Y, Annualized) | 63.09% | 47.99% |
| Beta (5Y) | 0.80 | 1.17 |
| Max Drawdown (5Y) | -56.54% | -79.22% |
| Avg. Volume (3M) | 2.76M | 7.82M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | INSM | ROIV |
|---|---|---|
| Sharpe Ratio (1Y) | -0.69 | 1.93 |
| Sortino Ratio (1Y) | -1.04 | 4.03 |
Profitability
ROE (TTM)
Both Insmed (INSM) at -72.45% and Roivant Sciences (ROIV) at -8.52% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-72.45%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- INSM
- -72.45%
- Min
- -167.77%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.52%
- Max
- 109.18%
- Q3
- 6.23%
- ROIV
- -8.52%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile Roivant Sciences (ROIV) reports 0.00%, ranking against industry peers normally.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- INSM
- -39.85%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- ROIV
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Insmed (INSM) at -15.60% and Roivant Sciences (ROIV) at -25,408.11% report negative operating margin values, usually indicating operating losses over the period.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
-15.60%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- INSM
- -15.60%
- Q1
- -78.82%
- Min
- -207.40%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-25,408.11%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- ROIV
- -25,408.11%
Profitability Metrics
| Metric | INSM | ROIV |
|---|---|---|
| ROE (TTM) | -72.45% | -8.52% |
| ROA (TTM) | -17.25% | -16.28% |
| Net Margin (TTM) | -39.85% | 0.00% |
| Operating Margin (TTM) | -15.60% | -25,408.11% |
| Gross Margin (TTM) | 84.40% | 0.00% |
Growth
Revenue Growth
Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while Roivant Sciences (ROIV) at -71.57% is in the bottom quartile, showing a clear gap in revenue momentum.
EPS Growth
Neither Insmed (INSM) nor Roivant Sciences (ROIV) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | INSM | ROIV |
|---|---|---|
| Revenue Growth (YoY) | 66.73% | -71.57% |
| Revenue Growth (3Y CAGR) | 35.20% | -36.01% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while Roivant Sciences (ROIV) at 16.72 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.86
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INSM
- 2.86
- Q1
- 2.47
- Min
- 0.10
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.72
- Max
- 25.13
- ROIV
- 16.72
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Roivant Sciences (ROIV) at 0.02 carries an industry-typical debt-to-equity mix, while Insmed (INSM) at 1.01 uses more debt funding than most peers.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01
- Max
- 1.42
- INSM
- 1.01
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- ROIV
- 0.02
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | INSM | ROIV |
|---|---|---|
| Current Ratio (MRQ) | 2.86 | 16.72 |
| Debt / Equity (MRQ) | 1.01 | 0.02 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither Insmed (INSM) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INSM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Insmed (INSM) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INSM
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ROIV
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | INSM | ROIV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Insmed (INSM) nor Roivant Sciences (ROIV) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- INSM
- --
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ROIV
- --
P/S Ratio (TTM)
Insmed (INSM) at 16.52 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.52
- Max
- 58.18
- Q3
- 25.77
- INSM
- 16.52
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
3,728.61
- ROIV
- 3,728.61
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both look rich against book: Roivant Sciences (ROIV) at 6.64 sits in the upper P/B ratio quartile, and Insmed (INSM) at 34.55 prices even higher, above its industry range.
INSM
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.55
- INSM
- 34.55
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ROIV
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64
- Max
- 13.53
- ROIV
- 6.64
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | INSM | ROIV |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 16.52 | 3,728.61 |
| P/B Ratio (MRQ) | 34.55 | 6.64 |
| Free Cash Flow Yield (TTM) | -1.82% | -3.98% |